Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Azacitidine in the treatment of MDS

David Steensma • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes APR-246 Azacitidine Checkpoint inhibitors Venetoclax

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses azacitidine as the main treatment regimen for high-risk myelodysplastic syndrome (MDS) and the possibility of combination therapy. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:43
MDS novel agents & HMAs
David Steensma • 5 Mar 2020
1:16
State of the art: MDS
David Steensma • 5 Mar 2020
1:32
Clonal hematopoiesis & MDS
David Steensma • 5 Mar 2020

Related Videos

5:29
A retrospective study assessing efficacy and safety of ESAs in VEXAS syndrome with or without MDS
Maël Heiblig • 17 Apr 2024
3:16
Developing patient-specific MRD markers for predicting and preventing MDS relapse post-SCT
Eva Hellström-Lindberg • 11 Apr 2024
3:28
Preclinical studies of tasquinimod in MDS: in vitro and in vivo investigations
Manja Wobus • 17 Apr 2024
2:11
The current treatment approaches for patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals